However, tucidinostat did not appear to activate T cells directly as no upregulation of the CD69 expression was observed on the conventional CD8+ or CD4+ T cells among PBMCs of patients with NSCLC (Fig. 7b). This evidence concerns the gene CD8A and non-small cell lung carcinoma.